Maxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress Plans

We recently compiled a list of the 8 Oversold Biotech Stocks to Invest In Now. Reviva Pharmaceuticals Holdings, Inc. is one of the oversold stocks to invest in.

TheFly reported on April 9 that Maxim Group downgraded RVPH from Buy to Hold. The firm pointed to ongoing weakness in the share price following the company’s one-for-20 reverse stock split completed on March 9. It noted that although recent funding may help advance a second Phase 3 study of brilaroxazine, additional capital will still be required. With the stock trading below the $1.00 NASDAQ compliance level, the analyst also highlighted heightened delisting risk alongside continued financing concerns as key factors behind the downgrade.

Earlier on March 30, Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) reported its full-year 2025 financial results along with key business and development updates. The company posted a net loss of approximately $19.9 million, or $5.48 per share, compared with a $29.9 million loss in 2024. Cash and cash equivalents totaled about $14.4 million as of December 31, 2025.

Maxim Turns Cautious on Reviva Pharmaceuticals Holdings, Inc. (RVPH) Despite Phase 3 Progress Plans

15 States with the Best Healthcare in the US

During 2025 and early 2026, RVPH completed multiple equity offerings, including $10.0 million raised in March 2026, with total cash expected to support operations into Q1 2027. The update also highlighted regulatory feedback from the FDA recommending a second Phase 3 trial for brilaroxazine in schizophrenia, alongside continued advancement of RECOVER-2 planned for mid-2026. Additional progress included patent expansion efforts, completed manufacturing and nonclinical studies, and ongoing

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) is a late-stage biopharmaceutical company developing therapies for central nervous system, inflammatory, respiratory, and cardiometabolic diseases. Its lead drug candidate, brilaroxazine, targets schizophrenia and other neuropsychiatric disorders.

While we acknowledge the risk and potential of RVPH as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RVPH and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Healthcare Stocks to Buy and Hold for 3 Years and 10 Best Beaten Down Stocks to Invest in According to Analysts.

Disclosure: None. Follow Insider Monkey on Google News.